Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDArmata Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q2 2025 | 1 | -$0.17 | -$0.17 | -$0.17 |
| Q3 2025 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2025 | 1 | -$0.26 | -$0.26 | -$0.26 |
Armata Pharmaceuticals, Inc. Earnings Date And Information
Armata Pharmaceuticals, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.15 earnings per share for the quarter, topping analysts' consensus estimates of $-0.28 by $0.13. The company had revenue of 0 for the quarter and had revenue of 4.53 M for the year. Armata Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.91 diluted earnings per share) and currently has a price-to-earnings ratio of -1.74. Armata Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 19th, 2025 based on prior year's report dates.
Armata Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.28 | -$0.15 | 0.13 | $900,000 | $0 |
| 08/13/2024 | Q2 2024 | -$0.52 | -$0.40 | 0.12 | $1.15 M | $0 |
| 05/07/2024 | Q1 2024 | -$0.28 | -$0.69 | -0.41 | $966,000 | |
| 03/21/2024 | Q4 2023 | -$0.35 | -$0.55 | -0.2 | $1.53 M | |
| 09/29/2023 | Q3 2023 | -$0.86 | $950,000 | $1.23 M | ||
| 08/14/2023 | Q2 2023 | -$0.35 | -$0.10 | 0.25 | $1.80 M | $980,000 |
| 05/11/2023 | Q1 2023 | -$0.29 | -$0.49 | -0.2 | $796,000 | |
| 03/16/2023 | Q4 2022 | -$0.25 | -$0.29 | -0.04 | $1.05 M | |
| 11/09/2022 | Q3 2022 | -$0.27 | -$0.24 | 0.03 | $1.64 M | $1.34 M |
| 08/11/2022 | Q2 2022 | -$0.26 | -$0.26 | 0 | $1.13 M | $1.88 M |
| 05/12/2022 | Q1 2022 | -$0.20 | -$0.30 | -0.1 | $0 | |
| 03/17/2022 | Q4 2021 | -$0.25 | -$0.25 | 0 | $0 | |
| 11/10/2021 | Q3 2021 | -$0.26 | -$0.22 | 0.04 | $1.08 M | $0 |
| 08/12/2021 | Q2 2021 | -$0.25 | -$0.25 | 0 | $410,000 | $0 |
| 05/13/2021 | Q1 2021 | -$0.28 | -$0.27 | 0.01 | $1.07 M | |
| 03/18/2021 | Q4 2020 | -$0.40 | $-31,000 | |||
| 11/12/2020 | Q3 2020 | -$0.17 | -$0.31 | -0.14 | $875,000 | $0 |
| 08/13/2020 | Q2 2020 | -$0.23 | -$0.26 | -0.03 | $750,000 | $31,000 |
| 05/14/2020 | Q1 2020 | -$0.35 | -$0.49 | -0.14 | $0 | |
| 03/19/2020 | Q4 2019 | -$0.76 | -$0.48 | 0.28 | $0 |
Armata Pharmaceuticals, Inc. Earnings: FAQ's
When is Armata Pharmaceuticals, Inc.'s earnings date?
Armata Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 19th, 2025 based off last year's report dates.
Did Armata Pharmaceuticals, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Armata Pharmaceuticals, Inc. (:ARMP) reported $-0.15 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.28 by $0.13.
How can I listen to Armata Pharmaceuticals, Inc.'s earnings conference
call?
The conference call for Armata Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read Armata Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Armata Pharmaceuticals, Inc.'s latest earnings report can be read online.
How much revenue does Armata Pharmaceuticals, Inc. generate each year?
Armata Pharmaceuticals, Inc. (:ARMP) has a recorded annual revenue of $4.53 M.
How much profit does Armata Pharmaceuticals, Inc. generate each year?
Armata Pharmaceuticals, Inc. (:ARMP) has a recorded net income of $4.53 M. Armata Pharmaceuticals, Inc. has generated $-1.91 earnings per share over the last four quarters.
What is Armata Pharmaceuticals, Inc.'s price-to-earnings ratio?
Armata Pharmaceuticals, Inc. (:ARMP) has a price-to-earnings ratio of -1.74 and price/earnings-to-growth ratio is -0.06.